Lakefront Biotherapeutics (LKFT) Total Non-Current Liabilities (2014 - 2026)

Lakefront Biotherapeutics (LKFT) has 13 years of Total Non-Current Liabilities data on file, last reported at $21.8 million in Q1 2026.

• Total Non-Current Liabilities for Q1 2026 came in at $21.8 million, down 97.52% year-over-year; the trailing twelve-month figure through Mar 2026 was $21.8 million (down 97.52% YoY), and the FY2025 annual result was $20.7 million, down 97.86% from the prior year.
• Total Non-Current Liabilities grew to $21.8 million in Q1 2026 per LKFT's latest filing, from $20.7 million in the prior quarter.
• Over five years, Total Non-Current Liabilities peaked at $2.1 billion in Q1 2022 and troughed at $20.7 million in Q4 2025.
• A 5-year average of $1.1 billion and a median of $1.1 billion in 2024 frame the typical range for Total Non-Current Liabilities.
• The sharpest annual moves came in 2024 and 2025: Total Non-Current Liabilities retreated 20.83% in 2024, then sank 97.86% in 2025.
• A 5-year view of Total Non-Current Liabilities shows it stood at $1.7 billion in 2022, then retreated by 29.08% to $1.2 billion in 2023, then decreased by 20.83% to $965.7 million in 2024, then slumped by 97.86% to $20.7 million in 2025, then climbed by 5.38% to $21.8 million in 2026.
• Business Quant data shows LKFT's Total Non-Current Liabilities at $21.8 million in Q1 2026, $20.7 million in Q4 2025, and $816.5 million in Q3 2025.